Caprock Group LLC Invests $353,000 in Mirum Pharmaceuticals, Inc. $MIRM

Caprock Group LLC purchased a new stake in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 4,778 shares of the company’s stock, valued at approximately $353,000.

Other institutional investors have also added to or reduced their stakes in the company. Emerald Advisers LLC purchased a new stake in shares of Mirum Pharmaceuticals during the 2nd quarter worth approximately $15,560,000. Soleus Capital Management L.P. bought a new stake in Mirum Pharmaceuticals in the second quarter worth $15,201,000. Bank of New York Mellon Corp grew its stake in shares of Mirum Pharmaceuticals by 101.1% in the 2nd quarter. Bank of New York Mellon Corp now owns 496,061 shares of the company’s stock worth $25,245,000 after buying an additional 249,331 shares in the last quarter. Emerald Mutual Fund Advisers Trust bought a new stake in shares of Mirum Pharmaceuticals in the 2nd quarter worth about $11,071,000. Finally, JPMorgan Chase & Co. raised its position in shares of Mirum Pharmaceuticals by 66.8% during the 2nd quarter. JPMorgan Chase & Co. now owns 480,276 shares of the company’s stock valued at $24,441,000 after buying an additional 192,340 shares in the last quarter.

Insider Buying and Selling

In other news, Director Patrick J. Heron purchased 131,425 shares of the stock in a transaction dated Friday, January 23rd. The shares were acquired at an average cost of $68.48 per share, for a total transaction of $8,999,984.00. Following the acquisition, the director owned 459,010 shares of the company’s stock, valued at approximately $31,433,004.80. This represents a 40.12% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Eric Bjerkholt sold 1,421 shares of the firm’s stock in a transaction that occurred on Thursday, January 22nd. The shares were sold at an average price of $93.33, for a total transaction of $132,621.93. Following the completion of the sale, the chief financial officer owned 42,127 shares of the company’s stock, valued at approximately $3,931,712.91. This trade represents a 3.26% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 45,136 shares of company stock valued at $4,352,029 over the last ninety days. Company insiders own 14.36% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have weighed in on MIRM shares. Cantor Fitzgerald reissued an “overweight” rating and set a $130.00 price objective on shares of Mirum Pharmaceuticals in a research note on Monday, December 8th. Stifel Nicolaus lifted their target price on Mirum Pharmaceuticals from $92.00 to $98.00 and gave the stock a “buy” rating in a report on Tuesday, December 16th. Robert W. Baird increased their price target on Mirum Pharmaceuticals from $80.00 to $88.00 and gave the company an “outperform” rating in a report on Monday, December 8th. Leerink Partners set a $100.00 price objective on shares of Mirum Pharmaceuticals in a research note on Wednesday, December 10th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Mirum Pharmaceuticals in a research report on Thursday, January 22nd. One research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, Mirum Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $110.17.

Mirum Pharmaceuticals Stock Up 2.2%

Shares of NASDAQ:MIRM opened at $105.10 on Thursday. The business’s 50 day moving average is $88.64 and its 200 day moving average is $77.02. The stock has a market cap of $5.40 billion, a P/E ratio of -122.21 and a beta of 0.49. Mirum Pharmaceuticals, Inc. has a 52-week low of $36.88 and a 52-week high of $107.41. The company has a quick ratio of 3.16, a current ratio of 3.31 and a debt-to-equity ratio of 1.06.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.